Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy.

Daiki MurataKoichi AzumaKenta MurotaniAkihiko KawaharaYuuya NishiiTakaaki TokitoTetsuro SasadaTomoaki Hoshino
Published in: Cancer immunology, immunotherapy : CII (2024)
We identified several soluble immune mediators as pre-treatment and on-treatment biomarkers of survival in patients with NSCLC treated with ICI monotherapy. Some of these biomarkers were associated with other possible predictors, including irAE development, PD-L1 expression, CD8+ TIL density and NLR. Further large-scale studies are needed to establish biomarkers for patients with NSCLC who received ICI monotherapy.